Leukemia Trials

Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 5 of 5

A Randomized Phase Iii Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (¡ý 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease.

Lead Researcher: Syed Ali, MD

Condition/Disease: Cancer - Leukemia

Location:

D’Amour Center for Cancer Care

3350 Main Street

Springfield MA 01199

Franklin Medical Center

164 High Street

Greenfield MA

E1912 A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia

The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and Ibrutinib

Lead Researcher: Syed Ali, MD

Condition/Disease: Cancer - Leukemia, Cancer

Location:

D’Amour Center for Cancer Care

3350 Main Street

Springfield MA 01199

And

Franklin Medical Center

164 High Street

Greenfield MA

NCI/CIRB EAY131 Molecular Analysis for Therapy Choice (MATCH)

Lead Researcher: John McCann, MD

Condition/Disease: Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate

Location:

D'Amour Center For Cancer Care

3350 Main Street
Springfield, MA 01199

NCI/CIRB S1609 DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS

Lead Researcher: John McCann, MD

Location:

D'Amour Center for Cancer Care

3350 Main Street
Springfield, MA 01199

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

The purpose of this study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone.

Lead Researcher: Syed Ali, MD

Condition/Disease: Cancer - Leukemia, Cancer

Location:

D’Amour Center for Cancer Care

3350 Main Street

Springfield MA 01199

Page 1 of 1 | Results 1 - 5 of 5